Joint statement calls for FDA to require drug trials to include people with obesity healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
The FDA has approved a supplemental new drug application for Rexulti for the treatment of agitation associated with dementia due to Alzheimer’s disease.According to a joint press release from Otsuka and Lundbeck, the approval makes Rexulti (brexpiprazole, Otsuka/Lundbeck) the first and only treatment approved in the United States for this common neuropsychiatric symptom of AD, which is
Vitamin D supplementation did not appear linked to mental health or metabolic outcomes at 6 months in people with first-episode psychosis, according to results of a randomized clinical trial published in JAMA Network Open. “We report the results of the DFEND (Vitamin D Supplementation Compared to Placebo in People With First Episode Psychosis–Neuroprotection Design) trial,”